Elizabeth Whyte

Elizabeth Whyte

Auto-generated profile, based on publicly available information

Elizabeth Whyte

Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2023 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
EWElizabeth Whyte
Elizabeth Whyte
MNMasahiro Nezu
Masahiro Nezu
CCConstance Chik
Constance Chik
TTToru Tateno
Toru Tateno
Pituitary neuroendocrine tumors (PitNETs) are the third most frequently diagnosed intracranial tumors, with nonfunctioning PitNETs (nfPitNETs) accounting for 30% of all pituitary tumors and representing the most common type of macroPitNETs. NfPitNETs are usually benign tumors with no evidence of hormone oversecretion except for hyperprolactinemia secondary to pituitary stalk compression. Due to this, they do not typically present with clinical syndromes like acromegaly, Cushing’s disease or hyperthyroidism and instead are identified incidentally on imaging or from symptoms of mass effects (headache, vision changes, apoplexy). With the lack of effective medical interventions, first-line treatment is transsphenoidal surgical resection, however, nfPitNETs often have supra- or parasellar extension, and total resection of the tumor is often not possible, resulting in residual tumor regrowth or reoccurrence. While functional PitNETs can be easily followed for recurrence using hormonal biomarkers, there is no similar parameter to predict recurrence in nfPitNETs, hence delaying early recognition and timely management. Therefore, there is a need to identify prognostic biomarkers that can be used for patient surveillance and as therapeutic targets. This review focuses on summarizing the current evidence on nfPitNETs, with a special focus on potential new biomarkers and therapeutics.

1 March 2022 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
EWElizabeth Whyte
Elizabeth Whyte
STScott Thomas
Scott Thomas
SMSusan Marzolini
Susan Marzolini